Brief: Syndax Pharmaceuticals Says Co Believes It Has Sufficient Cash Runway Through 2026

Syndax Pharmaceuticals

02/01/2024 12:29

Jan 2 (Reuters) - Syndax Pharmaceuticals Inc  SNDX.O :
    * SYNDAX PHARMACEUTICALS: COMPLETION OF $230 MILLION
FOLLOW-ON
OFFERING IN DECEMBER EXTENDS RUNWAY THROUGH 2026
    * SYNDAX PHARMACEUTICALS: COMPLETION OF ENROLLMENT IN
AUGMENT-101
MNPM1 PATIENT COHORT EXPECTED IN LATE 1Q/EARLY 2Q, TOPLINE DATA
ANTICIPATED IN 4Q24
    * SYNDAX PHARMACEUTICALS INC: NDA SUBMITTED FOR REVUMENIB IN
R/R
KMT2AR ACUTE LEUKEMIA UNDER U.S. FDA'S RTOR PROGRAM
    * SYNDAX PHARMACEUTICALS INC: BLA SUBMITTED FOR AXATILIMAB
IN
CHRONIC GRAFT-VERSUS-HOST DISEASE
    * SYNDAX PHARMACEUTICALS INC: SYNDAX EXERCISED OPTION TO
CO-COMMERCIALIZE AXATILIMAB IN U.S. WITH INCYTE
    * SYNDAX PHARMACEUTICALS INC:  BELIEVES THAT IT HAS
SUFFICIENT
CASH RUNWAY TO FUND ITS CLINICAL AND COMMERCIAL OPERATIONS
THROUGH 2026

Source text for Eikon:  ID:nPn1TRWswa 
Further company coverage:  SNDX.O 

 ((Reuters.Briefs@thomsonreuters.com;))